How the Phase 3 Trial Assessing an Investigational Dose of Semaglutide Injection for Type 2 Diabetes Was Conducted

Name: How the Phase 3 Trial Assessing an Investigational Dose of Semaglutide Injection for Type 2 Diabetes Was Conducted
Uploaded: 2021-07-01T18:00:00.000Z
Description: Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes was conducted.

July 1, 2021

Video

Conference|ADA Scientific Sessions - American Diabetes Association Scientific Sessions

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes was conducted.

Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.

During the discussion, Radin addresses how the phase 3 SUSTAIN FORTE trial was conducted.